Denali Advisors’s Esperion Therapeutics ESPR Stock Holding History

Denali Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,500	Closed	-$49K	–	392
2022 Q1	$49K	Buy	+10,500	New	+$45K	0.02%	243

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Denali Advisors's ESPR Position: Q2 2022 in Review

Denali Advisors sold out of Esperion Therapeutics (ESPR) in Q2 2022, closing a stake of 10,500 shares — an estimated $49K sold.

Denali Advisors first reported a position in ESPR in Q1 2022 and held it in 1 quarter. The position peaked at $49K in Q1 2022. 136 funds tracked by Wall St. Rank hold ESPR as of Q2 2022.

Denali Advisors reported no remaining Esperion Therapeutics position as of Q2 2022 after selling out during the quarter.
Denali Advisors sold 10,500 Esperion Therapeutics shares in Q2 2022, an estimated $49K.
Denali Advisors first reported a position in Esperion Therapeutics in Q1 2022 and held it in 1 quarter.
Denali Advisors's Esperion Therapeutics position peaked at $49K in Q1 2022.
136 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2022.

Based on Denali Advisors's 13F filing for Q2 2022, filed 18 Jul 2022.